2 results
Approved WMOCompleted
To prove superiority of Fermathron plus in the treatment of patients with mild knee OA compared to placebo
Approved WMORecruiting
The primary objective of this study is to assess the efficacy of Triumeq versus placebo on overall survival, defined as death from any cause, in participants with ALS at 24 months or after a minimum of 212 events.